Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
Demo Company
GLOBETECH PUBLISHING LLC

New Reaction Vessel Heating System Is Cleaner and Safer

By BiotechDaily International staff writers
Posted on 20 Aug 2014
Image: The DrySyn MULTI converts any standard hotplate stirrer into a high performance reaction block (Photo courtesy of Asynt).
Image: The DrySyn MULTI converts any standard hotplate stirrer into a high performance reaction block (Photo courtesy of Asynt).
Biotech and other life science researchers can create a safer, cleaner, and more efficient working environment in their laboratories by switching from oil bath-based heating of reaction vessels to a new high performance reaction block that can be used with any hotplate stirrer.

The Asynt (Isleham, United Kingdom) DrySyn MULTI converts any standard hotplate stirrer into a high performance reaction block accommodating three round-bottomed flasks (10 to 500 milliliters) or up to 12 reaction tubes or vials.

DrySyn MULTI heating blocks, which are made of chemically resistant, anodized aluminum, offer excellent heating performance to over 300 degrees Celsius. They are able to heat a reaction flask faster than an oil bath with less energy consumption and without the inherent risks and mess of an oil bath.

The DrySyn MULT system is based on an ingenious three-way clamp that secures flasks in place. Furthermore, DrySyn MULTI's shallow well shape increases reaction visibility and minimizes the possibility of glass failure.

Related Links:

Asynt



Channels

Genomics/Proteomics

view channel
Image: An activated PTEN dimer that contains two non-mutant proteins (A) can transform the functional lipid (D) on the cellular membrane (E) into a chemical form that tunes down cancer predilection. Dimers that contain a mutated protein (B) or PTEN monomers cannot transform the functional lipid (Photo courtesy of Carnegie Mellon University).

PTEN Requires a Stable Dimer Configuration to Effectively Suppress Tumor Growth

Molecular structural analysis has shown that the PTEN (phosphatase and tensin homolog) tumor suppressor can function effectively only when two wild-type alleles are present to form a stable dimer that... Read more

Business

view channel

MS Drug Deal to Net More Than USD 1 Billion

A pharmaceutical company based in Switzerland has purchased the remaining rights to the multiple sclerosis drug Ofatumumab, which will allow it to continue development of the compound for treating relapsing remitting multiple sclerosis (RRMS) and similar autoimmune diseases. Novartis (Basel, Switzerland) recently announced... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.